# A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

> **NCT04702880** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 135 (actual)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** BMS-986012
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04702880
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2025-05-22
- **Final completion:** 2025-11-28
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702880, "A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04702880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*